Hereditary Angioedema Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hereditary Angioedema stocks.

Hereditary Angioedema Stocks Recent News

Date Stock Title
May 7 IONS Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript
May 7 BCRX BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript
May 7 IONS Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
May 7 IONS Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
May 7 IONS Ionis Pharmaceuticals GAAP EPS of -$0.98 beats by $0.09, revenue of $119M misses by $17.41M
May 7 IONS Ionis reports first quarter 2024 financial results
May 7 BCRX BioCryst Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
May 7 BCRX BioCryst: Estimate-Beating Q1 But Risks Are Considerable
May 7 BCRX BioCryst Pharmaceuticals Inc (BCRX) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
May 7 BCRX Q1 2024 BioCryst Pharmaceuticals Inc Earnings Call
May 6 BCRX Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
May 6 BCRX BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance
May 6 BCRX BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript
May 6 BCRX BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2024 Earnings Call Transcript
May 6 IONS Ionis Pharmaceuticals Q1 2024 Earnings Preview
May 6 BCRX BioCryst surges 18% on quarterly earnings, adjusted guidance outlook
May 6 BCRX BioCryst Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
May 6 IONS Wall Street's Insights Into Key Metrics Ahead of Ionis Pharmaceuticals (IONS) Q1 Earnings
May 6 BCRX BioCryst Pharmaceuticals Reports Strong Q1 2024 Results, Exceeding Analyst Revenue Forecasts
May 6 BCRX BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
Hereditary Angioedema

Hereditary angioedema (HAE) is a disorder that results in recurrent attacks of severe swelling. The swelling most commonly affects the arms, legs, face, intestinal tract, and airway. Itchiness does not typically occur. If the intestinal tract is affected abdominal pain and vomiting may occur. Swelling of the airway can result in its obstruction. Attacks, without treatment, typically occur every couple of weeks and last for a few days.There are three main types of HAE. Type I and II are caused by a mutation in the SERPING1 gene that makes the C1 inhibitor protein while type III is often due to a mutation of the factor XII gene. This results in increased amounts of bradykinin which promotes swelling. The condition may be inherited from a person's parents in an autosomal dominant manner or occur as a new mutation. Triggers of an attack may include minor trauma or stress, but often occurs without any obvious preceding event. Diagnosis of type I and II is based upon measuring C4 and C1-inhibitor levels.Management involves efforts to prevent attacks and the treatment of attacks if they occur. During an attack supportive care such as intravenous fluids and airway support may be required. The medication C1 inhibitor can be used for both prevention and treatment. Ecallantide and icatibant can be used to treat acute attacks.This disorder affects approximately one in 50,000 people. The condition is typically first noticed in childhood. Type I and II affected females and males equally. Type III affects females more often than males. When the airway is involved, without treatment, death occurs in about 25%. With treatment outcomes are generally good. The condition was first described in 1888 by William Osler.

Browse All Tags